Stock Research for DRRX

DRRX

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

DRRX Stock Chart & Research Data

The DRRX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the DRRX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


DRRX Due diligence Resources & Stock Charts

The DRRX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View DRRX Detailed Price Forecast - CNN Money CNN View DRRX Detailed Summary - Google Finance
Yahoo View DRRX Detailed Summary - Yahoo! Finance Zacks View DRRX Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View DRRX Trends & Analysis - Trade-Ideas Barrons View DRRX Major Holders - Barrons
NASDAQ View DRRX Call Transcripts - NASDAQ Seeking View DRRX Breaking News & Analysis - Seeking Alpha
Spotlight View DRRX Annual Report - CompanySpotlight.com OTC Report View DRRX OTC Short Report - OTCShortReport.com
TradeKing View DRRX Fundamentals - TradeKing Charts View DRRX SEC Filings - Bar Chart
WSJ View Historical Prices for DRRX - The WSJ Morningstar View Performance/Total Return for DRRX - Morningstar
MarketWatch View the Analyst Estimates for DRRX - MarketWatch CNBC View the Earnings History for DRRX - CNBC
StockMarketWatch View the DRRX Earnings - StockMarketWatch MacroAxis View DRRX Buy or Sell Recommendations - MacroAxis
Bullish View the DRRX Bullish Patterns - American Bulls Short Pains View DRRX Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View DRRX Stock Mentions - StockTwits PennyStocks View DRRX Stock Mentions - PennyStockTweets
Twitter View DRRX Stock Mentions - Twitter Invest Hub View DRRX Investment Forum News - Investor Hub
Yahoo View DRRX Stock Mentions - Yahoo! Message Board Seeking Alpha View DRRX Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for DRRX - SECform4.com Insider Cow View Insider Transactions for DRRX - Insider Cow
CNBC View DRRX Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for DRRX - OTC Markets
Yahoo View Insider Transactions for DRRX - Yahoo! Finance NASDAQ View Institutional Holdings for DRRX - NASDAQ


Stock Charts

FinViz View DRRX Stock Insight & Charts - FinViz.com StockCharts View DRRX Investment Charts - StockCharts.com
BarChart View DRRX Stock Overview & Charts - BarChart Trading View View DRRX User Generated Charts - Trading View


Latest Financial News for DRRX

DURECT Corporation to Host Key Opinion Leader Call on Alcoholic Hepatitis
Posted on Thursday March 29, 2018

CUPERTINO, Calif., March 29, 2018 /PRNewswire/ -- DURECT Corporation (DRRX) today announced it will host a key opinion leader (KOL) call on the treatment of alcoholic hepatitis (AH) on Thursday, April 5 at 11:00 a.m. Eastern Time. The call will feature a presentation by KOL Paul Kwo, MD, who will present an overview of alcoholic hepatitis, including an overview of the disease and its progression, current treatment options and new treatments in development for alcoholic hepatitis.  Dr. Kwo will be available to answer questions at the conclusion of the call. DURECT's management team will also provide an overview of the Company's ongoing clinical development program for DUR-928, including a summary of preclinical and clinical data disclosed to-date and a review of the Company's Phase 2 study in patients with alcoholic hepatitis.  DUR-928 is the lead product candidate in DURECT's Epigenetic Regulator Program.  It is an endogenous, first-in-class small molecule that has been shown in nonclinical studies to modulate the activity of nuclear receptors playing an important regulatory role in lipid homeostasis, inflammation, and cell survival.


Investor Expectations to Drive Momentum within Aon plc, Endeavour Silver, BlackBerry, DURECT, Castle Brands, and Nabors Industries — Discovering Underlying Factors of Influence
Posted on Monday March 26, 2018

NEW YORK, March 26, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...


DURECT Announces FDA Advisory Committee Meeting for REMOXY® ER
Posted on Tuesday March 20, 2018

CUPERTINO, Calif. , March 20, 2018 /PRNewswire/ --   DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE), reported yesterday that the U.S. Food and Drug ...


Is DURECT Corporation (NASDAQ:DRRX) Undervalued?
Posted on Monday March 12, 2018

DURECT Corporation (NASDAQ:DRRX), a pharmaceuticals company based in United States, led the NasdaqGM gainers with a relatively large price hike in the past couple of weeks. As a small capRead More...


Enter a stock symbol to view the stock details.